Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1

Table 2 Associations between parameters and high dolutegravir (DTG) plasma trough concentrations (≥ 1.06 μg/mL)

	Univariate results			Multivariate results
	OR	95% CI	p-value	OR	95% CI	p-value
Age ≥ 40 years	0.35	0.15–0.82	0.0144	0.35	0.13–0.92	0.0324
Body weight < 65 kg	0.71	0.33–1.53	0.3864	1.02	0.41–2.57	0.9705
Sex (Male)	3.95	0.90–27.5	0.0693	3.84	0.73–30.5	0.1175
HIV-1-RNA level at the time of sampling (< 50 copies/mL)	0.98	0.04–25.2	0.9894	0.53	0.02–15.7	0.6786
Number of UGT1A1*6 alleles
0	1			1
1	2.52	1.02–6.46	0.0434	3.33	1.24–9.51	0.0164
2	4.4 × 10⁷	5.21-∞	0.0003	5.9 × 10⁷	6.90-∞	0.0001
Number of UGT1A1*28 alleles
0	1			1
1	2.03	0.78–5.57	0.1476	3.61	1.24–11.5	0.0184
2	2.32	0.21–50.9	0.4862	4.01	0.33–93.4	0.2669

OR odds ratio, CI confidence interval, UGT1A1 uridine diphosphate-glucuronosyltransferase 1A1, HIV human immunodeficiency virus

ISSN: 1471-2334